Publication | Open Access

Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model

Endocrine OncologyPancreatic CancerMedicineNeuroendocrine DisorderPathologyPancreatic Neuroendocrine TumorsNeuroendocrine TumorsOncologyRadiation OncologyCancer ResearchTumor BiologyEndocrine-related Cancer